Literature DB >> 31043225

Treatment of first-time traumatic anterior shoulder dislocation: the UK TASH-D cohort study.

Jonathan L Rees1,2, Anjali Shah1,2, Katherine Edwards1,2, Maria T Sanchez-Santos1,2, Danielle E Robinson1,2, Antonella Delmestri1,2, Andrew Carr1,2, Nigel Arden1,2,3, Sarah E Lamb1,2,4, Amar Rangan1,2,5,6, Andrew Judge1,2, Rafael Pinedo-Villanueva1,2, Tim Holt7, Sally Hopewell1,2,4, Daniel Prieto-Alhambra1,2, Gary Collins1,2.   

Abstract

BACKGROUND: Shoulder dislocations are the most common joint dislocations seen in emergency departments. Most traumatic cases are anterior and cause recurrent dislocations. Management options include surgical and conservative treatments. There is a lack of evidence about which method is most effective after the first traumatic anterior shoulder dislocation (TASD).
OBJECTIVES: To produce UK age- and sex-specific incidence rates for TASD. To assess whether or not surgery within 6 months of a first-time TASD decreases re-dislocation rates compared with no surgery. To identify clinical predictors of recurrent dislocation.
DESIGN: A population-based cohort study of first-time TASD patients in the UK. An initial validation study and subsequent propensity-score-matched analysis to compare re-dislocation rates between surgery and no surgery after a first-time TASD. Prediction modelling was used to identify potential predictors of recurrent dislocation.
SETTING: UK primary and secondary care data. PARTICIPANTS: Patients with a first-time TASD between 1997 and 2015.
INTERVENTIONS: Stabilisation surgery within 6 months of a first-time TASD (compared with no surgery). Stabilisation surgery within 12 months of a first-time TASD was also carried out as a sensitivity analysis. MAIN OUTCOME MEASURE: Re-dislocation rate up to 2 years after the first TASD.
METHODS: Eligible patients were identified from the Clinical Practice Research Datalink (CPRD) (1997-2015). Accuracy of shoulder dislocation coding was internally validated using the CPRD General Practitioner questionnaire service. UK age- and sex-specific incidence rates for TASD were externally validated against rates from the USA and Canada. A propensity-score-matched analysis using linked CPRD and Hospital Episode Statistics (HES) data compared re-dislocation rates for patients aged 16-35 years, comparing surgery with no surgery. Multivariable Cox regression models for predicting re-dislocation were developed for the surgical and non-surgical cohorts.
RESULTS: Shoulder dislocation was coded correctly for 89% of cases in the CPRD [95% confidence interval (CI) 83% to 95%], with a 'primary' dislocation confirmed for 76% of cases (95% CI 67% to 85%). Far fewer patients than expected received stabilisation surgery within 6 months of a first TASD, leading to an underpowered study. Around 20% of re-dislocation rates were observed for both surgical and non-surgical patients. The sensitivity analysis at 12 months also showed little difference in re-dislocation rates. Missing data on risk factors limited the value of the prediction modelling; however, younger age, epilepsy and sex (male) were identified as statistically significant predictors of re-dislocation. LIMITATIONS: Far fewer than the expected number of patients had surgery after a first-time TASD, resulting in an underpowered study. This and residual confounding from missing risk factors mean that it is not possible to draw valid conclusions.
CONCLUSIONS: This study provides, for the first time, UK data on the age- and sex-specific incidence rates for TASD. Most TASD occurs in men, but an unexpected increased incidence was observed in women aged > 50 years. Surgery after a first-time TASD is uncommon in the NHS. Re-dislocation rates for patients receiving surgery after their first TASD are higher than previously expected; however, important residual confounding risk factors were not recorded in NHS primary and secondary care databases, thus preventing useful recommendations. FUTURE WORK: The high incidence of TASD justifies investigation into preventative measures for young men participating in contact sports, as well as investigating the risk factors in women aged > 50 years. A randomised controlled trial would account for key confounders missing from CPRD and HES data. A national TASD registry would allow for a more relevant data capture for this patient group. STUDY REGISTRATION: Independent Scientific Advisory Committee (ISAC) for the Medicines and Healthcare Products Regulatory Agency (ISAC protocol 15_0260). FUNDING: The National Institute for Health Research Health Technology Assessment programme.

Entities:  

Keywords:  CLINICAL PRACTICE RESEARCH DATALINK; CPRD; HES; INCIDENCE; SHOULDER DISLOCATION; SHOULDER SURGERY

Mesh:

Year:  2019        PMID: 31043225      PMCID: PMC6511890          DOI: 10.3310/hta23180

Source DB:  PubMed          Journal:  Health Technol Assess        ISSN: 1366-5278            Impact factor:   4.014


  4 in total

1.  Morphological characteristics and management of greater tuberosity fractures associated with anterior glenohumeral joint dislocation: A single centre 10-year retrospective review.

Authors:  Khalis Boksh; Ananth Srinivasan; Ganapathy Perianayagam; Harvinder Singh; Amit Modi
Journal:  J Orthop       Date:  2022-08-06

2.  Surgical delay for traumatic recurrent shoulder dislocations leads to inferior functional outcomes.

Authors:  Ravi Gupta; Shrenuj Goel; Anil Kapoor; Ashwani Soni; Gladson David Masih; Ravi Jethwa
Journal:  J Clin Orthop Trauma       Date:  2022-04-08

3.  Shoulder Dislocation Incidence and Risk Factors-Rural vs. Urban Populations of Poland.

Authors:  Karol Szyluk; Paweł Niemiec; Dominik Sieroń; Dawid Lukoszek; Marcin Gierek; Andrzej Lorek; Andreas Christe
Journal:  Int J Environ Res Public Health       Date:  2022-09-20       Impact factor: 4.614

4.  [Short-term effectiveness of arthroscopically capsular vertical mattress suturing for shoulder recurrent anterior dislocation combined with joint laxity].

Authors:  Yan Li; Lin Ma; Mingyu Yang; Miduo Mu; Aining Yang; Binghua Zhou; Kanglai Tang
Journal:  Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi       Date:  2020-11-15
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.